| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.093 | 0.002 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.35 | 0.004 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.16 | 0.005 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.007 |